Jiuwei Cui Selected Research

aumolertinib

1/2022	AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
1/2022	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jiuwei Cui Research Topics

Disease

114	Neoplasms (Cancer) 05/2024 - 09/2012
35	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 01/2015
24	Neoplasm Metastasis (Metastasis) 05/2024 - 07/2015
19	Breast Neoplasms (Breast Cancer) 02/2023 - 01/2015
17	Lung Neoplasms (Lung Cancer) 01/2023 - 01/2014
16	Disease Progression 01/2024 - 01/2019
9	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 09/2014
7	Inflammation (Inflammations) 02/2024 - 08/2012
7	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 01/2014
7	Leukemia 12/2018 - 01/2010
6	Lymphatic Metastasis 05/2024 - 07/2015
5	Neutropenia 04/2023 - 01/2021
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 05/2015
5	Carcinoma (Carcinomatosis) 01/2021 - 03/2010
4	Pneumonia (Pneumonitis) 01/2022 - 01/2014
4	Adenocarcinoma of Lung 01/2022 - 01/2017
4	Stomach Neoplasms (Stomach Cancer) 01/2021 - 03/2010
3	Triple Negative Breast Neoplasms 01/2024 - 01/2021
3	Hypertension (High Blood Pressure) 01/2024 - 01/2021
3	Cachexia 09/2023 - 05/2022
3	Diarrhea 01/2023 - 01/2021
3	Virus Diseases (Viral Diseases) 01/2023 - 01/2015
3	Infections 01/2023 - 01/2017
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2019
3	Exanthema (Rash) 01/2022 - 01/2021
3	Carcinogenesis 10/2021 - 01/2015
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 07/2018 - 03/2014
2	Sarcopenia 01/2024 - 12/2023
2	Autoimmune Diseases (Autoimmune Disease) 04/2023 - 09/2021
2	Anemia 04/2023 - 01/2021
2	Nasopharyngeal Carcinoma 02/2023 - 07/2016

Drug/Important Bio-Agent (IBA)

17	Immune Checkpoint InhibitorsIBA 01/2024 - 08/2018
13	Long Noncoding RNAIBA 01/2023 - 09/2014
11	Tyrosine Kinase InhibitorsIBA 01/2024 - 08/2018
11	Biomarkers (Surrogate Marker)IBA 12/2023 - 11/2013
11	Proteins (Proteins, Gene)FDA Link 05/2022 - 09/2012
10	ErbB Receptors (EGF Receptor)IBA 12/2023 - 04/2018
8	PlatinumIBA 12/2023 - 01/2020
8	LigandsIBA 02/2023 - 01/2016
7	RNA (Ribonucleic Acid)IBA 12/2023 - 01/2015
6	sintilimabIBA 01/2024 - 01/2021
5	DNA (Deoxyribonucleic Acid)IBA 04/2023 - 12/2014
5	Hormones (Hormone)IBA 02/2023 - 01/2020
5	Pemetrexed (MTA)FDA Link 01/2023 - 01/2019
5	CytokinesIBA 01/2022 - 11/2012
5	ChromatinIBA 10/2021 - 12/2014
4	AlbuminsIBA 05/2024 - 05/2022
4	serum P-component (CIt)IBA 05/2024 - 01/2014
4	Chimeric Antigen ReceptorsIBA 02/2024 - 11/2020
4	tislelizumabIBA 01/2024 - 01/2020
4	InterferonsIBA 04/2023 - 01/2016
4	Alanine Transaminase (SGPT)IBA 01/2023 - 01/2016
4	Bevacizumab (Avastin)FDA Link 01/2023 - 12/2019
4	Biosimilar PharmaceuticalsIBA 01/2023 - 12/2019
4	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 01/2022
4	Interleukin-2 (IL2)IBA 01/2020 - 09/2012
4	Small Interfering RNA (siRNA)IBA 01/2019 - 03/2010
4	Streptozocin (Streptozotocin)FDA Link 07/2018 - 07/2013
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2024 - 12/2019
3	Carboplatin (JM8)FDA LinkGeneric 01/2024 - 12/2019
3	LipidsIBA 01/2024 - 01/2020
3	130-nm albumin-bound paclitaxelIBA 01/2024 - 01/2021
3	4-toluenesulfonyl fluoride (TSF)IBA 01/2023 - 01/2022
3	sugemalimabIBA 01/2023 - 01/2022
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2023 - 01/2016
3	Antiviral Agents (Antivirals)IBA 01/2023 - 01/2014
3	Antineoplastic Agents (Antineoplastics)IBA 01/2023 - 01/2020
3	Gefitinib (Iressa)FDA Link 11/2022 - 01/2022
3	human ERBB2 proteinIBA 01/2022 - 01/2021
3	AntibodiesIBA 01/2022 - 01/2020
3	AntigensIBA 01/2021 - 02/2017
3	OligodeoxyribonucleotidesIBA 11/2020 - 01/2017
3	Messenger RNA (mRNA)IBA 01/2020 - 01/2015
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 06/2018 - 01/2014
3	Insulin-Like Growth Factor II (Somatomedin A)IBA 05/2017 - 01/2014
3	Peptides (Polypeptides)IBA 01/2017 - 11/2015
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 05/2024 - 01/2021
2	Anaplastic Lymphoma KinaseIBA 01/2024 - 01/2022
2	CrizotinibIBA 01/2024 - 01/2023
2	sitravatinibIBA 01/2024 - 01/2023
2	toripalimabIBA 01/2024 - 01/2023
2	Blood Glucose (Blood Sugar)IBA 01/2024 - 03/2014
2	icotinibIBA 10/2023 - 04/2021
2	Transcription Factors (Transcription Factor)IBA 09/2023 - 01/2014
2	Monoclonal AntibodiesIBA 02/2023 - 12/2019
2	B7-H1 AntigenIBA 01/2023 - 01/2021
2	umifenovirIBA 01/2023 - 01/2017
2	Therapeutic UsesIBA 01/2023 - 01/2016
2	Neoplasm Antigens (Tumor Antigens)IBA 01/2023 - 07/2018
2	Interleukin-10 (Interleukin 10)IBA 01/2023 - 01/2017
2	pembrolizumabIBA 01/2023 - 01/2022
2	camrelizumabIBA 12/2022 - 01/2021
2	IGF Type 1 Receptor (IGF 1 Receptor)IBA 11/2022 - 09/2018

Therapy/Procedure

56	Therapeutics 02/2024 - 01/2014
40	Immunotherapy 02/2024 - 01/2014
37	Drug Therapy (Chemotherapy) 05/2024 - 05/2015
6	Radiotherapy 12/2023 - 01/2016
3	Chemoradiotherapy 01/2024 - 07/2016
3	Adjuvant Chemotherapy 01/2022 - 07/2016
3	Precision Medicine 11/2019 - 09/2018